Antengene’s multiple myeloma therapy receives approval in Hong Kong

17 Jul 2023
www.pharmaceutical-technology.com
Drug Approval
Antengene’s multiple myeloma therapy receives approval in Hong Kong
Preview
Source: Pharmaceutical Technology
Xpovio plus dexamethasone is indicated for relapsed and/or refractory multiple myeloma. Credit: Nemes Laszlo / Shutterstock.com.
Antengene has received approval from the Department of Health, the Government of the Hong Kong Special Administrative Region, for a new drug application for Xpovio (selinexor) along with dexamethasone (Xd) to treat relapsed and/or refractory multiple myeloma (R/R MM).
The treatment is indicated for use in adults who have received a minimum of four therapies previously, have a progression of the condition following the prior therapy and have disease refractory to a minimum of two immunomodulatory agents, an anti-CD38 monoclonal antibody and two proteasome inhibitorsproteasome inhibitors.
Recommended Reports
Antengene’s multiple myeloma therapy receives approval in Hong Kong
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - PHE-885 in Refractory Multiple Myeloma GlobalData
Antengene’s multiple myeloma therapy receives approval in Hong Kong
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - EEDVD-682 in Head And Neck Cancer GlobalData
View allCompanies IntelligenceAntengene Corp LtdThe Department of HealthView all
Xpovio is the first oral nuclear export protein inhibitor to receive approval in Hong Kong.
It is currently approved in 41 countries and regions, including Canada, Israel, the US, the UK, the European Union, Norway and Iceland.
Antengene Asia Pacific Region head and corporate vice-president Thomas Karalis stated: “Despite recent advances in the treatment of R/R MM, there remains an unmet need to extend survival for patients with this life-threatening disease and the approval of Xpovio presents Hong Kong patients with access to a novel therapy in their treatment of R/R MM.
“We will continue to build out Antengene’s presence across APAC markets and strive to expand the indications of Xpovio in Hong Kong and the broader APAC region, in efforts to bring renewed hope to more cancer patients.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.